|
1
|
Ditsawanon P and Aramwit P: Preserving the
peritoneal membrane in long-term peritoneal dialysis patients. J
Clin Pharm Ther. Aug 17–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yuvaraj A, Koshy PJ, Rohit A, Nagarajan P,
Nair S, Revathi L and Abraham G: Diagnostic dilemma of
ultrafiltration failure in a continuous ambulatory peritoneal
dialysis patient. Perit Dial Int. 35:233–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Teitelbaum I: Ultrafiltration failure in
peritoneal dialysis: A pathophysiologic approach. Blood Purif.
39:70–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fusshoeller A: Histomorphological and
functional changes of the peritoneal membrane during long-term
peritoneal dialysis. Pediatr Nephrol. 23:19–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ranzinger J, Rustom A and Schwenger V:
Membrane nanotubes between peritoneal mesothelial cells: Functional
connectivity and crucial participation during inflammatory
reactions. Front Physiol. 5:4122014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morelle J and Devuyst O: Water and solute
transport across the peritoneal membrane. Curr Opin Nephrol
Hypertens. 24:434–443. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaneda K, Miyamoto K, Nomura S and
Horiuchi T: Intercellular localization of occludins and ZO-1 as a
solute transport barrier of the mesothelial monolayer. J Artif
Organs. 9:241–250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Devuyst O and Rippe B: Water transport
across the peritoneal membrane. Kidney Int. 85:750–758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han JY, Kim YJ, Kim L, Choi SJ, Park IS,
Kim JM, Chu YC and Cha DR: PPARgamma agonist and angiotensin II
receptor antagonist ameliorate renal tubulointerstitial fibrosis. J
Korean Med Sci. 25:35–41. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma L, Shao Z, Wang R, Zhao Z, Dong W and
Zhang J, Zhang X, Sheng S, Ji Z and Zhang J: Rosiglitazone improves
learning and memory ability in rats with type 2 diabetes through
the insulin signaling pathway. Am J Med Sci. 350:121–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang YF, Zou XL, Wu J, Yu XQ and Yang X:
Rosiglitazone, a peroxisome proliferator-activated receptor
(PPAR)-γ agonist, attenuates inflammation via NF-kB inhibition in
lipopolysaccharide-induced peritonitis. Inflammation. 38:2105–2115.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aramwit P, Bunmee P and Supasyndh O:
Effectiveness and tolerability of rosiglitazone on insulin
resistance and body composition in nondiabetic Thai patients
undergoing continuous ambulatory peritoneal dialysis: A 12-week
pilot study. Curr Ther Res Clin Exp. 70:377–389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nie J, Dou X, Hao W, Wang X, Peng W, Jia
Z, Chen W, Li X, Luo N, Lan HY and Yu XQ: Smad7 gene transfer
inhibits peritoneal fibrosis. Kidney Int. 72:1336–1344. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo J, Xiao J, Gao H, Jin Y and Zhao Z,
Jiao W, Liu Z and Zhao Z: Cyclooxygenase-2 and vascular endothelial
growth factor expressions are involved in ultrafiltration failure.
J Surg Res. 188:527–536.e2. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Devuyst O and Yool AJ: Aquaporin-1: New
developments and perspectives for peritoneal dialysis. Perit Dial
Int. 30:135–141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ni J, Verbavatz JM, Rippe A, Boisdé I,
Moulin P, Rippe B, Verkman AS and Devuyst O: Aquaporin-1 plays an
essential role in water permeability and ultrafiltration during
peritoneal dialysis. Kidney Int. 69:1518–1525. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiu L, Chen C, Ding G, Zhou Y and Zhang M:
The effects of electromagnetic pulse on the protein levels of tight
junction associated-proteins in the cerebral cortex, hippocampus,
heart, lung, and testis of rats. Biomed Environ Sci. 24:438–444.
2011.PubMed/NCBI
|
|
19
|
Hawkins BT and Davis TP: The blood-brain
barrier/neurovascular unit in health and disease. Pharmacol Rev.
57:173–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ito T, Yorioka N, Kyuden Y, Asakimori Y,
Kiribayashi K, Ogawa T and Kohno N: Effect of glucose polymer on
the intercellular junctions of cultured human peritoneal
mesothelial cells. Nephron Clin Pract. 93:c97–c105. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leung JC, Chan LY, Li FF, Tang SC, Chan
KW, Chan TM, Lam MF, Wieslander A and Lai KN: Glucose degradation
products downregulate ZO-1 expression in human peritoneal
mesothelial cells: The role of VEGF. Nephrol Dial Transplant.
20:1336–1349. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leitch V, Agre P and King LS: Altered
ubiquitination and stability of aquaporin-1 in hypertonic stress.
Proc Natl Acad Sci USA. 98:2894–2898. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakayama M, Kawaguchi Y, Yamada K,
Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H,
Ogawa A, et al: Immunohistochemical detection of advanced
glycosylation end-products in the peritoneum and its possible
pathophysiological role in CAPD. Kidney Int. 51:182–186. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Hooland S, Boey O, Van der Niepen P,
Van den Branden C and Verbeelen D: Effect of short-term
rosiglitazone therapy in peritoneal dialysis patients. Perit Dial
Int. 29:108–111. 2009.PubMed/NCBI
|
|
25
|
Sandoval P, Loureiro J, González-Mateo G,
Pérez-Lozano ML, Maldonado-Rodríguez A, Sánchez-Tomero JA, Mendoza
L, Santamaría B, Ortiz A, Ruíz-Ortega M, et al: PPAR-γ agonist
rosiglitazone protects peritoneal membrane from dialysis
fluid-induced damage. Lab Invest. 90:1517–1532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sauter M, Kastenmüller K, Belling F,
Wörnle M, Ladurner R, Mussack T and Sitter T: Activation of
peroxisome proliferator-activated receptor-gamma by glitazones
reduces the expression and release of monocyte chemoattractant
protein-1 in human mesothelial cells. Mediators Inflamm.
2012:2176962012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yao Q, Ayala ER, Qian JQ, Stenvinkel P,
Axelsson J and Lindholm B: A combination of a PPAR-gamma agonist
and an angiotensin II receptor blocker attenuates proinflammatory
signaling and stimulates expression of Smad7 in human peritoneal
mesothelial cells. Clin Nephrol. 68:295–301. 2007.PubMed/NCBI
|
